Literature DB >> 16943302

Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes.

Zhijian Wu1, Aravind Asokan, Joshua C Grieger, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, R Jude Samulski.   

Abstract

Despite the high degree of sequence homology between adeno-associated virus (AAV) serotype 1 and 6 capsids (99.2%), these viruses have different liver transduction profiles when tested as vectors. Examination of the six amino acid residues that differ between AAV1 and AAV6 revealed that a lysine-to-glutamate change (K531E) suppresses the heparin binding ability of AAV6. In addition, the same mutation in AAV6 reduces transgene expression to levels similar to those achieved with AAV1 in HepG2 cells in vitro and in mouse liver following portal vein administration. In corollary, the converse E531K mutation in AAV1 imparts heparin binding ability and increases transduction efficiency. Extraction of vector genomes from liver tissue suggests that the lysine 531 residue assists in preferential transduction of parenchymal cells by AAV6 vectors in comparison with AAV1. Lysine 531 is unique to AAV6 among other known AAV serotypes and is located in a basic cluster near the spikes that surround the icosahedral threefold axes of the AAV capsid. Similar to studies with autonomous parvoviruses, this study describes the first example of single amino acid changes that can explain differential phenotypes such as viral titer, receptor binding, and tissue tropism exhibited by closely related AAV serotypes. In particular, a single lysine residue appears to provide the critical minimum charged surface required for interacting with heparin through electrostatic interaction and simultaneously plays an unrelated yet critical role in the liver tropism of AAV6 vectors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943302      PMCID: PMC1642158          DOI: 10.1128/JVI.01288-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

2.  SWISS-MODEL: An automated protein homology-modeling server.

Authors:  Torsten Schwede; Jürgen Kopp; Nicolas Guex; Manuel C Peitsch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

3.  Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity.

Authors:  N Kaludov; K E Brown; R W Walters; J Zabner; J A Chiorini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.

Authors:  C L Halbert; J M Allen; A D Miller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

Authors:  J Walter; Q You; J N Hagstrom; M Sands; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

6.  Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Authors:  Dirk Grimm; Shangzhen Zhou; Hiroyuki Nakai; Clare E Thomas; Theresa A Storm; Sally Fuess; Takashi Matsushita; James Allen; Richard Surosky; Michael Lochrie; Leonard Meuse; Alan McClelland; Peter Colosi; Mark A Kay
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

7.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Combinations of two capsid regions controlling canine host range determine canine transferrin receptor binding by canine and feline parvoviruses.

Authors:  Karsten Hueffer; Lakshman Govindasamy; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.

Authors:  Shaun R Opie; Kenneth H Warrington; Mavis Agbandje-McKenna; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  114 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

3.  Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing.

Authors:  Luk H Vandenberghe; Ru Xiao; Martin Lock; Jianping Lin; Michael Korn; James M Wilson
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

4.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

Review 5.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

6.  Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Authors:  Sanford L Boye; Antonette Bennett; Miranda L Scalabrino; K Tyler McCullough; Kim Van Vliet; Shreyasi Choudhury; Qing Ruan; James Peterson; Mavis Agbandje-McKenna; Shannon E Boye
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

7.  Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1.

Authors:  Edward B Miller; Brittney Gurda-Whitaker; Lakshmanan Govindasamy; Robert McKenna; Sergei Zolotukhin; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

8.  AAV-6 mediated efficient transduction of mouse lower airways.

Authors:  Wuping Li; Liqun Zhang; Zhijian Wu; Raymond J Pickles; R Jude Samulski
Journal:  Virology       Date:  2011-07-14       Impact factor: 3.616

9.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

10.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.